Beam Therapeutics Inc. (NASDAQ:BEAM) Insider Amy Simon Sells 502 Shares

Beam Therapeutics Inc. (NASDAQ:BEAM) insider Amy Simon sold 502 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $23.76, for a total value of $11,927.52. Following the completion of the sale, the insider now directly owns 69,553 shares of the company’s stock, valued at approximately $1,652,579.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Beam Therapeutics Stock Performance

Shares of BEAM opened at $23.48 on Thursday. Beam Therapeutics Inc. has a 12-month low of $16.95 and a 12-month high of $49.50. The business’s fifty day moving average price is $23.62 and its 200 day moving average price is $27.76.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($1.21) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.21. Beam Therapeutics had a negative net margin of 37.33% and a negative return on equity of 15.46%. The business had revenue of $7.40 million during the quarter, compared to analyst estimates of $17.09 million. During the same period in the previous year, the business posted ($1.33) EPS. The company’s quarterly revenue was down 69.4% on a year-over-year basis. As a group, research analysts anticipate that Beam Therapeutics Inc. will post -4.68 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on BEAM. BMO Capital Markets reissued an “outperform” rating and set a $57.00 price target on shares of Beam Therapeutics in a research report on Wednesday, March 27th. TheStreet upgraded shares of Beam Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 11th. Wedbush reaffirmed an “outperform” rating and set a $57.00 price target on shares of Beam Therapeutics in a research note on Tuesday, May 7th. Finally, Barclays cut their target price on Beam Therapeutics from $42.00 to $33.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 8th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $40.18.

Hedge Funds Weigh In On Beam Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of BEAM. GAMMA Investing LLC raised its position in shares of Beam Therapeutics by 958.7% during the 2nd quarter. GAMMA Investing LLC now owns 4,076 shares of the company’s stock worth $96,000 after purchasing an additional 3,691 shares during the period. Farallon Capital Management LLC increased its position in Beam Therapeutics by 9.9% in the first quarter. Farallon Capital Management LLC now owns 4,511,753 shares of the company’s stock worth $149,068,000 after buying an additional 406,000 shares during the period. Virtu Financial LLC bought a new stake in Beam Therapeutics in the first quarter valued at $875,000. Bayesian Capital Management LP acquired a new position in shares of Beam Therapeutics during the first quarter valued at $291,000. Finally, Redmile Group LLC grew its position in shares of Beam Therapeutics by 31.5% during the first quarter. Redmile Group LLC now owns 1,879,617 shares of the company’s stock worth $62,103,000 after acquiring an additional 449,834 shares during the last quarter. 99.68% of the stock is currently owned by institutional investors and hedge funds.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.